Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 13,484 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: cGVHD Clear all
Completed Phase 1 Interventional

MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

NCT00101179
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Leukemia, Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions
Azacitidine, Entinostat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2019 · Synced Oct 28, 2026, 9:39 PM EDT
Not listed Not applicable Interventional

tDCS and Bimanual Therapy for Children With Hemiplegic Cerebral Palsy

NCT03402854
View directory record Official record
Conditions
Cerebral Palsy, Hemiplegic Cerebral Palsy, Spastic Hemiplegic Cerebral Palsy, Spastic Hemiparesis, Spastic Hemiplegia
Interventions
active transcranial direct current stimulation, bimanual training
Device · Behavioral
Lead sponsor
Burke Medical Research Institute
Other
Eligibility
6 Years to 18 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 28, 2026, 9:39 PM EDT
Terminated Phase 1Phase 2 Interventional

Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL

NCT01585688
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Interventions
hLL1-DOX (IMMU-115)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
6
States / cities
Newark, Delaware • Orlando, Florida • Goshen, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 28, 2026, 9:39 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Housing, Environment, And Living Conditions for Transformed Health

NCT06925373
View directory record Official record
Conditions
Lung Diseases, Chronic Disease
Interventions
Indoor Air Purification, Neighborhood Improvements, Housing Improvements
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
460 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 28, 2026, 9:39 PM EDT
Completed No phase listed Observational Results available

Impact of Patient Activation and Engagement on Patient-Centered Outcomes of Care in ACOs

NCT02287883
View directory record Official record
Conditions
Diabetes, Cardiovascular Disease
Interventions
Observational: Patient Activation and Engagement (PAE)
Other
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 82 Years
Enrollment
2,176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Berkeley, California • Torrance, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Oct 28, 2026, 9:39 PM EDT
Completed Phase 2 Interventional

Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

NCT01859962
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
PPI-668, BI 207127 Dose 1, BI 207127 Dose 2, Faldaprevir, Ribavirin, BI 207127 Placebo
Drug
Lead sponsor
Presidio Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 28, 2026, 9:39 PM EDT
Not listed Not applicable Interventional

External Sensing and Neuromodulation to Assess Diabetic Pain Outcomes (XANADO)

NCT05537662
View directory record Official record
Conditions
Chronic Pain
Interventions
Standard of care neuromodulation therapy (SCS or DRG)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 28, 2026, 9:39 PM EDT
Not listed Phase 2 Interventional

Treatment Of Chronic Pain Using Real Time fMRI

NCT00528346
View directory record Official record
Conditions
Chronic Pain
Interventions
cognitive training using fMRI, placebo
Behavioral
Lead sponsor
Omneuron
Industry
Eligibility
21 Years to 60 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 28, 2026, 9:39 PM EDT
Completed Not applicable Interventional Results available

Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease

NCT01350388
View directory record Official record
Conditions
Chronic Kidney Disease, Diabetes
Interventions
Febuxostat, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Oct 28, 2026, 9:39 PM EDT
Completed Phase 2 Interventional Results available

ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients

NCT01464827
View directory record Official record
Conditions
Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1
Interventions
ABT-450, ABT-333, ABT-267, Ribavirin, Ritonavir
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 70 Years
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
60
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 28, 2026, 9:39 PM EDT
Completed Not applicable Interventional Results available

Increasing Live Donor Kidney Transplantation Through Video-based Education and Mobile Communication

NCT05154773
View directory record Official record
Conditions
End-stage Renal Disease, Chronic Kidney Diseases
Interventions
Kidney donation and transplant information made easy
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
Not listed
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 28, 2026, 9:39 PM EDT
Recruiting Phase 2 Interventional

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

NCT06834373
View directory record Official record
Conditions
Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent ALK-Positive Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Intravascular Large B-Cell Lymphoma, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory ALK-Positive Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Intravascular Large B-Cell Lymphoma, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, Golcadomide, Leukapheresis, Positron Emission Tomography, Rituximab
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 9:39 PM EDT
Completed Phase 1 Interventional

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

NCT03739554
View directory record Official record
Conditions
Relapsed or Refractory Chronic Lymphocytic Leukemia
Interventions
CYC065, Venetoclax
Drug
Lead sponsor
Cyclacel Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Baltimore, Maryland • Charlotte, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 28, 2026, 9:39 PM EDT
Recruiting Phase 2 Interventional

Pulmonary Hypertension SOLAR

NCT04778046
View directory record Official record
Conditions
Interstitial Lung Disease, COPD, Pulmonary Arterial Hypertension
Interventions
Hyperpolarized 129Xe
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 28, 2026, 9:39 PM EDT
Terminated Not applicable Interventional Results available

A Pilot Study of the Feasibility of Chronic Cavernous Nerve Stimulation to Promote Regeneration and Erectile Function

NCT02006927
View directory record Official record
Conditions
Prostate Cancer
Interventions
Nerve Stimulation
Device
Lead sponsor
Kenneth M Peters, MD
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 28, 2026, 9:39 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

NCT03836261
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Acalabrutinib, Venetoclax, Chemoimmunotherapy, Obinutuzumab
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 130 Years
Enrollment
984 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
16
States / cities
Los Angeles, California • Redondo Beach, California • Fort Wayne, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 28, 2026, 9:39 PM EDT
Completed No phase listed Observational

Investigation of the Cylex® ImmuKnow® Assay

NCT00569842
View directory record Official record
Conditions
Leukemia, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Hodgkin's Disease, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Aplastic Anemia, Chronic Myelogenous Leukemia
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Oct 28, 2026, 9:39 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Rheumatology Patient Registry and Biorepository

NCT04402086
View directory record Official record
Conditions
Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 28, 2026, 9:39 PM EDT
Completed Phase 2 Interventional

Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients

NCT05119686
View directory record Official record
Conditions
Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Interventions
AR882 Dose 1, AR882 Dose 2, Placebo
Drug
Lead sponsor
Arthrosi Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
16
States / cities
Gilbert, Arizona • Sun City, Arizona • Tucson, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 28, 2026, 9:39 PM EDT
Suspended Not applicable Interventional

Lyme Disease Patients With Memory Problems

NCT03500770
View directory record Official record
Conditions
Lyme Disease
Interventions
Transcranial Direct Current Stimulator
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 28, 2026, 9:39 PM EDT
Completed No phase listed Observational

Inflammatory Biomarkers Predict Pulmonary Outcomes in Coronary Artery Bypass Grafting

NCT01366469
View directory record Official record
Conditions
Coronary Artery Disease, Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2014 · Synced Oct 28, 2026, 9:39 PM EDT
Completed Not applicable Interventional Results available

Digital Clinical Hypnosis for Chronic Pain Management

NCT06050083
View directory record Official record
Conditions
Chronic Low-back Pain, Chronic Pain
Interventions
Hypnosis audio recordings
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 28, 2026, 9:39 PM EDT
Completed Phase 3 Interventional Results available

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

NCT00799903
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15,828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
155
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 132 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 28, 2026, 9:39 PM EDT
Completed No phase listed Observational

Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

NCT06122961
View directory record Official record
Conditions
Cardiovascular Risk, Heart Failure, Chronic Kidney Disease
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
18,198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Fremont, California • McKinney, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 28, 2026, 9:39 PM EDT